Skip to main content

revdofilimab

Generic: Revdofilimab

revdofilimab: 2 clinical trials tracked.

revdofilimab evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about revdofilimab, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 1 study sponsors

Related indications

Advanced Solid TumorsCancer
Clinical Trial Registry Records (2)

A Phase 1b, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Subjects With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

NCT04196283Registry updated 2023-02-27·Phase 1·ABBV
Completed

Primary endpoint: Number of Participants with Adverse Events (AEs)

Interventionalopen30 enrolledStarted 2020-01Completion 2022-1026 sites · France, Germany, Israel, Netherlands…AbbVie

A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT03893955Registry updated 2026-09-02·Phase 1·ABBV
Active, not recruiting

Primary endpoint: Dose Expansion: Objective Response Rate (ORR)

Interventionalopen150 targetStarted 2019-05Completion 2027-0326 sites · Australia, France, Israel, Spain…AbbVie